Skip to main content
main-content
Erschienen in: Forensic Toxicology 1/2021

24.11.2020 | Short Communication

Identification of six tryptamine derivatives as designer drugs in illegal products

verfasst von: Rie Tanaka, Maiko Kawamura, Takashi Hakamatsuka, Ruri Kikura-Hanajiri

Erschienen in: Forensic Toxicology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To prevent the abuse of new designer drugs, Japan has declared 2385 substances and two plants as “Designated Substances” as of March 2020. Although the distribution of these substances has decreased over the past 5 years, newly detected designer drugs are still being found. We have detected six designer drugs in six powdery products between February of 2017 and April of 2019.

Methods

The structures of the compounds were determined by gas chromatography mass spectrometry (GC–MS), liquid chromatography mass spectrometry (LC–MS), liquid chromatography with hybrid quadrupole time-of-flight mass spectrometry (LC-Q-TOF–MS) and nuclear magnetic resonance (NMR) spectroscopy.

Results

Six tryptamine derivatives (4-acetoxy-N,N-dipropyltryptamine, 4-hydroxy-N,N-dipropyltryptamine, 4-hydroxy-N-methyl-N-propyltryptamine, N-ethyl-N-propyltryptamine, 4-hydroxy-N-ethyl-N-propyltryptamine (4OH-EPT), and 4-hydroxy-N-methyl-N-cyclopropyltryptamine (4OH-McPT) were identified. Among these, 4OH-EPT and 4OH-McPT were identified as newly distributed designer drugs.

Conclusions

The continuous provisional monitoring of newly detected compounds in illicit products will largely prevent the distribution of these products.
Literatur
3.
Zurück zum Zitat Araújo AM, Carvalho F, Bastos ML, Pinho PG, Carvalho M (2015) The hallucinogenic world of tryptamines: an updated review. Arch Toxicol 89:1151–1173 CrossRef Araújo AM, Carvalho F, Bastos ML, Pinho PG, Carvalho M (2015) The hallucinogenic world of tryptamines: an updated review. Arch Toxicol 89:1151–1173 CrossRef
4.
Zurück zum Zitat Glennon RA, Gessner PK (1979) Serotonin receptor binding affinities of tryptamine analogues. J Med Chem 22(4):428–432 CrossRef Glennon RA, Gessner PK (1979) Serotonin receptor binding affinities of tryptamine analogues. J Med Chem 22(4):428–432 CrossRef
5.
Zurück zum Zitat Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2013) URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int 227:21–32 CrossRef Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2013) URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int 227:21–32 CrossRef
6.
Zurück zum Zitat Repke DB, Ferguson WJ, Bates DK (1977) Synthesis of 3-[2-(dialkylamino)ethyl]-and 3-[2- (cycloalkylamino)ethyl]indol-4-ols. J Heterocyclic Chem 14:71–74 CrossRef Repke DB, Ferguson WJ, Bates DK (1977) Synthesis of 3-[2-(dialkylamino)ethyl]-and 3-[2- (cycloalkylamino)ethyl]indol-4-ols. J Heterocyclic Chem 14:71–74 CrossRef
7.
Zurück zum Zitat Repke DB, Ferguson WJ, Bates DK (1981) Psilocin analogs II. Synthesis of 3-[2-(dialkylamino)ethyl]-, 3-[2- (N-methyl-N-alkylamino)ethyl]-, and 3-[2-(cycloalkylamino)ethyl]indol-4-ols. J Heterocyclic Chem 18:175–179 CrossRef Repke DB, Ferguson WJ, Bates DK (1981) Psilocin analogs II. Synthesis of 3-[2-(dialkylamino)ethyl]-, 3-[2- (N-methyl-N-alkylamino)ethyl]-, and 3-[2-(cycloalkylamino)ethyl]indol-4-ols. J Heterocyclic Chem 18:175–179 CrossRef
8.
Zurück zum Zitat Brandt SD, Freeman S, Fleet IA, McGagh P, Alder JF (2005) Analytical chemistry of synthetic routes to psychoactive tryptamines Part II. Characterization of the Speeter and Anthony synthetic route to N, N-dialkylated tryptamines using GC-EI-ITMS. ESI-TQ-MS-MS and NMR. Analyst 130:330–344 PubMed Brandt SD, Freeman S, Fleet IA, McGagh P, Alder JF (2005) Analytical chemistry of synthetic routes to psychoactive tryptamines Part II. Characterization of the Speeter and Anthony synthetic route to N, N-dialkylated tryptamines using GC-EI-ITMS. ESI-TQ-MS-MS and NMR. Analyst 130:330–344 PubMed
9.
Zurück zum Zitat Kikura-Hanajiri R, Uchiyama N, Kawamura M, Ogata J, Goda Y (2013) Prevalence of new designer drugs and heir legal status in Japan. Yakugaku Zasshi 133:31–40 CrossRef Kikura-Hanajiri R, Uchiyama N, Kawamura M, Ogata J, Goda Y (2013) Prevalence of new designer drugs and heir legal status in Japan. Yakugaku Zasshi 133:31–40 CrossRef
Metadaten
Titel
Identification of six tryptamine derivatives as designer drugs in illegal products
verfasst von
Rie Tanaka
Maiko Kawamura
Takashi Hakamatsuka
Ruri Kikura-Hanajiri
Publikationsdatum
24.11.2020
Verlag
Springer Singapore
Erschienen in
Forensic Toxicology / Ausgabe 1/2021
Print ISSN: 1860-8965
Elektronische ISSN: 1860-8973
DOI
https://doi.org/10.1007/s11419-020-00556-5

Weitere Artikel der Ausgabe 1/2021

Forensic Toxicology 1/2021 Zur Ausgabe

Neu im Fachgebiet Rechtsmedizin

Open Access 15.08.2022 | Mammakarzinom | CME

Prädiktive molekulare Diagnostik beim Mammakarzinom

Welche Anforderungen stellen sich heute und in Zukunft für die Pathologie?

10.08.2022 | Schwerpunkt: Akkreditierung und Zertifizierung (Qualitätssicherung)

Ringversuche – ein zentrales Mittel der externen Qualitätssicherung

03.08.2022 | Schwerpunkt: Akkreditierung und Zertifizierung (Qualitätssicherung)

Akkreditierung in der Pathologie und Neuropathologie

Wege und Pitfalls

25.07.2022 | Schwerpunkt: Akkreditierung und Zertifizierung (Qualitätssicherung)

Die Akkreditierung in der Pathologie und Neuropathologie in Deutschland

Rahmenbedingungen und Voraussetzungen